Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.91 |
| ▸ | FECH | P22830 | 1/20 | 0.67 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.67 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.67 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.67 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905945 | 0.95 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL12846011 | 0.90 | MTOR (0.90) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL2902918 | 0.88 | MTOR (0.75) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL14089044 | 0.88 | MTOR (0.75) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL10225104 | 0.88 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL2908008 | 0.88 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL2908254 | 0.86 | MTOR (0.89) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL22030453 | 0.86 | MTOR (0.89) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL1217194 | 0.86 | MTOR (0.89) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| SCHEMBL14207545 | 0.86 | MTOR (0.90) | MTORFECHPIK3R1PIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081809-A1 | Novel Compounds | SLC10A1, ABCB11, PKD1 | MTOR 203/4885FECH 1311/4885PIK3R1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.